



## Doncaster Place and Bassetlaw Place Medicines Optimisation Bulletin

November 2024



Have you got a spare couple of minutes? Like what you see? Want to hear more from Medicines Optimisation? We need your feedback on the new style bulletin. Use the QR code opposite or follow the link:  
<https://forms.office.com/e/A21uYN9JJb>

Useful hyperlinks for Medicines Optimisation  
To open Press control and click the link below  
[IMOC Webpage](#)  
[Doncaster Place Website](#)  
[MPD](#)

### Traffic Light Status (TLS) additions and changes

TLS Integrated medicines Optimisation Committee (IMOC) List November 2024

Please Note: TLS status finalised at IMOC all items are classified as non-Formulary unless stated otherwise.

The MPD will be updated accordingly.

For a full list of items that were classified in November 2024 click this link below:

[November 2024 TLS List](#)

### New and updated Documents now available on the MO website / MPD

- New: Opioid Prescribing Resource in Chronic Non-Cancer Pain - Including Tapering Advice [Click Here](#)
- New: Algorithm for the management of Young Adults with Type 2 Diabetes (18-39 years) [Click Here](#)
- New: Guidance for supporting women with type 2 diabetes to prepare for pregnancy. [Click here](#)
- Updated : ADHD SCP and Proforma [Click here](#)
- Updated : Guidance for prescribing Parecoxib 40mg Injection in palliative care patients [Click Here](#)

#### DIBS Update

You can find latest DIBS Practice information and other useful resources on the DIBS page on the Medicines Management website by clicking this [link](#)  
If you have any questions around DIBS, please contact the MO team via our email :  
[syicb-doncaster.medicinesmanagementadmin@nhs.net](mailto:syicb-doncaster.medicinesmanagementadmin@nhs.net)

#### MHRA Drug Safety Update From IMOC November 2024:

**Bromocriptine: monitor blood pressure when prescribing bromocriptine for prevention or inhibition of post-partum physiological lactation**

A safety review has highlighted that blood pressure monitoring of patients prescribed with this drug is essential especially during the first days of treatment. It should only be prescribed for the prevention or suppression of postpartum lactation where medically indicated, in cases such as intrapartum loss, neonatal death, or a mother with HIV infection. [Click here](#) for further information.

#### Using Genetics to Guide Medication After a Stroke or Mini stroke (TIA) at DBTHFT

There is growing evidence that genetic testing for CYP2C19 gene changes can help guide the use of Clopidogrel, a medication frequently prescribed for people who have had a stroke or mini stroke (TIA). On 31 July 2024, NICE (the National Institute for Health and Care Excellence) published guidance recommending this genetic test after an ischaemic stroke or TIA.

NICE and NHS England are running a pilot project to test an early version of the service. This pilot will take place at four sites in England, including **Doncaster and Bassetlaw Teaching Hospitals (DBTHFT)** where the project is led by Dr. Ahmad Maatouk, Stroke Lead, with support from specialists at the National Stroke Programme, NHS England Genomics Unit and NHS Network of Excellence in Pharmacogenomics. You may see some correspondence coming from DBTHFT over the coming months. Dr. Ahmad Maatouk will be presenting an update at a forthcoming Target session in the new year but for further written information on this pilot [click here](#)



**Formulary updates November 2024**

**The following items were agreed to be added/amended on the MPD**

Formulary Section	Item	Indication	PMOC Action
4.6.1	Xonvea	<b>Nausea and Vomiting in pregnancy:</b> This is a licensed drug for Nausea and vomiting in pregnancy and is highlighted in the Green-Top guidance	Link to Green-top guidance included on MPD Green non-formulary
10.3.2	Capsaicin Cream 0.025 & 0.075	Previously in NICE guidance for osteoarthritis No longer available in the UK and is now an imported drug	Grey on MPD
1.5.2	Budesonide Rectal products		Green non-formulary on MPD
6.1.2.3	Empagliflozin	Type 2 diabetes Formulary choices have been changed on the MPD in line with National Guidelines	Formulary 1st line
6.1.2.3	Dapagliflozin		Formulary 1st line
6.1.2.3	Canagliflozin		Formulary 2nd line
6.1.2.3	Ertugliflozin		Formulary 2nd line
13.10.4	Ivermectin 3mg tablets	Ivermectin 3mg tablets are now licensed and can be used as formulary 3 <sup>rd</sup> line for resistant scabies.	Green 3 <sup>rd</sup> line for Scabies only

**Tips to help with DIBS and QIPP work streams**

- **Luforbec is first line formulary choice for ICS/LABA MDI with Fostair being second line formulary choice. For Asthma guidance in adults [click here](#)**
- **High strength Toothpaste should not routinely be prescribed unless initiated by a dentist or secondary care specialist for patients who have undergone oral surgery. It should not be used for any other family members due to its high fluoride content.**
- **Doncaster Emollient Guidance for long term conditions has been updated and some new products now being first line formulary choice, Aqueous cream are no longer recommended due to risk of skin irritation. For full guidance document [Click here](#)**

**For the latest Out of Stock information  
Refer to your regular emails from medicines management Admin emails.**

**Ozempic / Wegovy / Mounjaro**

Ozempic (Injectable Semaglutide) is **only** licensed for the treatment of type 2 diabetes and classified as GREEN for this indication on the MPD. [Click here](#) to go to 6.1.2.3 **It does not appear on the MPD in any other category.**

Wegovy (Injectable Semaglutide) is **only** licensed for weight loss but classified as RED on the MPD, and therefore **should not be prescribed in primary care.**

Mounjaro (Injectable Tirzepatide) is licensed for weight loss and diabetes but is classified as Amber-G for diabetes. Information relating to its use in weight loss is pending in Doncaster dependant on NICE Guidance being developed and does not appear in any other category.

**Contact us : South Yorkshire Integrated Care Board Doncaster Place Medicines Optimisation Team**

Phone : 03000 213394

E-mail : [svicb-doncaster.medicinesmanagementadmin@nhs.net](mailto:svicb-doncaster.medicinesmanagementadmin@nhs.net) (general enquiries) or [svicb-doncaster.rxline@nhs.net](mailto:svicb-doncaster.rxline@nhs.net) (Clinical Enquiries)